# XL999 Administered Intravenously to a Subject With Advanced Malignancies

> **NCT01945164** · — · NO_LONGER_AVAILABLE · sponsor: **John Sarantopoulos**

## Conditions studied

- Advanced Malignancy

## Interventions

- **DRUG:** XL999

## Key facts

- **NCT ID:** NCT01945164
- **Lead sponsor:** John Sarantopoulos
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** 2010-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** — (—)
- **Last updated:** 2014-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945164, "XL999 Administered Intravenously to a Subject With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01945164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*